US Capitol Capsule: Paying For Precision Medicine: The Coverage Conundrum
This article was originally published in Scrip
Executive Summary
While the science of personalized medicine has been moving at an extremely rapid pace in recent years – evidenced by the fact that 20% of the novel therapies approved by the FDA in 2014 were targeted therapies – the efforts by the biopharmaceutical industry and others in the biomedical community, including the National Institutes of Health (NIH), will all be for naught if payers don't catch up, leaving patients without access, a panel of stakeholders said last week in Washington.